Analgesic therapy in postherpetic neuralgia: a quantitative systematic review

Postherpetic neuralgia (PHN) is a complication of acute herpes zoster, which is emerging as a preferred clinical trial model for chronic neuropathic pain. Although there are published meta-analyses of analgesic therapy in PHN, and neuropathic pain in general, the evidence base has been substantially...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:PLoS medicine 2005-07, Vol.2 (7), p.e164-e164
Hauptverfasser: Hempenstall, Kathleen, Nurmikko, Turo J, Johnson, Robert W, A'Hern, Roger P, Rice, Andrew S C
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e164
container_issue 7
container_start_page e164
container_title PLoS medicine
container_volume 2
creator Hempenstall, Kathleen
Nurmikko, Turo J
Johnson, Robert W
A'Hern, Roger P
Rice, Andrew S C
description Postherpetic neuralgia (PHN) is a complication of acute herpes zoster, which is emerging as a preferred clinical trial model for chronic neuropathic pain. Although there are published meta-analyses of analgesic therapy in PHN, and neuropathic pain in general, the evidence base has been substantially enhanced by the recent publication of several major trials. Therefore, we have conducted a systematic review and meta-analysis for both efficacy and adverse events of analgesic therapy for PHN. We systematically searched databases (MEDLINE 1966-2004, EMBASE 1988-2004, CINAHL 1982-2002, and PubMed [29 October 2004]) for trials of PHN. We also searched references of retrieved studies and review articles for further trials. We included trials that examined adult patients with PHN of greater duration than 3 mo, that were blinded, randomised, and had at least one measure of pain outcome. Dichotomous pain outcome data were extracted for 50% decrease in baseline pain using a hierarchy of pain/pain-relief measurement tools. Where available, dichotomous data were also collected for adverse events. Calculated estimates of efficacy included relative benefit and number needed to treat. Of 62 studies identified, 35 were randomised controlled trials. Of these, 31 were placebo controlled and suitable for meta-analysis, from which it was possible to extract dichotomous efficacy outcome data from 25. This meta-analysis revealed that there is evidence to support the use of the following orally administered therapies: tricyclic antidepressants, "strong" opioids, gabapentin, tramadol, and pregabalin. Topical therapies associated with efficacy were lidocaine 5% patch and capsaicin. Finally, a single study of spinal intrathecal administration of lidocaine and methyl prednisolone demonstrated efficacy, although this has yet to be replicated. Data suggest that the following therapies are not associated with efficacy in PHN: certain NMDA receptor antagonists (e.g., oral memantine, oral dextromethorphan, intravenous ketamine), codeine, ibuprofen, lorazepam, certain 5HT1 receptor agonists, and acyclovir. Topical administration of benzydamine, diclofenac/diethyl ether, and vincristine (iontophoresis) are similarly not associated with efficacy, nor are intrathecal administration of lidocaine alone or epidural administration of lidocaine and methylprednisolone, intravenous therapy with lidocaine, subcutaneous injection of Cronassial, or acupuncture. However, many of the trials that demonstr
doi_str_mv 10.1371/journal.pmed.0020164
format Article
fullrecord <record><control><sourceid>proquest_plos_</sourceid><recordid>TN_cdi_plos_journals_1288073534</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_98a920349355452aa3710b78bb3a854d</doaj_id><sourcerecordid>68026172</sourcerecordid><originalsourceid>FETCH-LOGICAL-c615t-b60b04591182c642e987ca8480f2cedc73e28ffca9d1941e405e24c864b848863</originalsourceid><addsrcrecordid>eNptkk9v1DAQxS0EoqXwDRBEqtTbLv4Xx-aAVFUFKrXiAmdr4ky2XmXj1E4W7bevtxugRT3ZHv_m2fP0CHnP6JKJin1ahyn20C2HDTZLSjllSr4gx6yUZsFUpV4-2h-RNymtM2Sooa_JEVOUCW3YMbk5zxorTN4V4y1GGHaF74shpP1pwDHXe5xiZjx8LqC4m6Af_Qij32KRdmnEDeyhiFuPv9-SVy10Cd_N6wn59fXy58X3xfWPb1cX59cLp1g5LmpFaypLw5jmTkmORlcOtNS05Q4bVwnkum0dmIYZyVDSErl0Wsk6Q1qJE_LxoDt0IdnZiWQZ15pWohQyE1cHogmwtkP0G4g7G8Dbh0KIKwsxf7xDazQYToU0oixlyQGyu7SudF0L0KVsstaX-bWpzmY77MdsyBPRpze9v7WrsLV5PqYrngXOZoEY7iZMo9345LDroMcwJas05Yo9gKf_gc_PJg-UiyGliO3frzBq99n402X32bBzNnLbh8dj_GuawyDuAajlt1Y</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1288073534</pqid></control><display><type>article</type><title>Analgesic therapy in postherpetic neuralgia: a quantitative systematic review</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Public Library of Science (PLoS)</source><creator>Hempenstall, Kathleen ; Nurmikko, Turo J ; Johnson, Robert W ; A'Hern, Roger P ; Rice, Andrew S C</creator><creatorcontrib>Hempenstall, Kathleen ; Nurmikko, Turo J ; Johnson, Robert W ; A'Hern, Roger P ; Rice, Andrew S C</creatorcontrib><description>Postherpetic neuralgia (PHN) is a complication of acute herpes zoster, which is emerging as a preferred clinical trial model for chronic neuropathic pain. Although there are published meta-analyses of analgesic therapy in PHN, and neuropathic pain in general, the evidence base has been substantially enhanced by the recent publication of several major trials. Therefore, we have conducted a systematic review and meta-analysis for both efficacy and adverse events of analgesic therapy for PHN. We systematically searched databases (MEDLINE 1966-2004, EMBASE 1988-2004, CINAHL 1982-2002, and PubMed [29 October 2004]) for trials of PHN. We also searched references of retrieved studies and review articles for further trials. We included trials that examined adult patients with PHN of greater duration than 3 mo, that were blinded, randomised, and had at least one measure of pain outcome. Dichotomous pain outcome data were extracted for 50% decrease in baseline pain using a hierarchy of pain/pain-relief measurement tools. Where available, dichotomous data were also collected for adverse events. Calculated estimates of efficacy included relative benefit and number needed to treat. Of 62 studies identified, 35 were randomised controlled trials. Of these, 31 were placebo controlled and suitable for meta-analysis, from which it was possible to extract dichotomous efficacy outcome data from 25. This meta-analysis revealed that there is evidence to support the use of the following orally administered therapies: tricyclic antidepressants, "strong" opioids, gabapentin, tramadol, and pregabalin. Topical therapies associated with efficacy were lidocaine 5% patch and capsaicin. Finally, a single study of spinal intrathecal administration of lidocaine and methyl prednisolone demonstrated efficacy, although this has yet to be replicated. Data suggest that the following therapies are not associated with efficacy in PHN: certain NMDA receptor antagonists (e.g., oral memantine, oral dextromethorphan, intravenous ketamine), codeine, ibuprofen, lorazepam, certain 5HT1 receptor agonists, and acyclovir. Topical administration of benzydamine, diclofenac/diethyl ether, and vincristine (iontophoresis) are similarly not associated with efficacy, nor are intrathecal administration of lidocaine alone or epidural administration of lidocaine and methylprednisolone, intravenous therapy with lidocaine, subcutaneous injection of Cronassial, or acupuncture. However, many of the trials that demonstrated a lack of efficacy represented comparatively low numbers of patient episodes or were single-dose studies, so it may be appropriate to regard such interventions as "not yet adequately tested" rather than demonstrating "no evidence of efficacy." Topical aspirin/diethyl ether has not been adequately tested. The evidence base supports the oral use of tricyclic antidepressants, certain opioids, and gabapentinoids in PHN. Topical therapy with lidocaine patches and capsaicin is similarly supported. Intrathecal administration of methylprednisolone appears to be associated with high efficacy, but its safety requires further evaluation.</description><identifier>ISSN: 1549-1676</identifier><identifier>ISSN: 1549-1277</identifier><identifier>EISSN: 1549-1676</identifier><identifier>DOI: 10.1371/journal.pmed.0020164</identifier><identifier>PMID: 16013891</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Analgesics ; Analgesics - pharmacology ; Antidepressants ; Antidepressive Agents - therapeutic use ; Antidepressive Agents, Tricyclic - therapeutic use ; Clinical Trials as Topic ; Herpes viruses ; Herpes Zoster - drug therapy ; Humans ; Lidocaine - therapeutic use ; Meta-analysis ; Methylprednisolone - administration &amp; dosage ; Narcotics ; Narcotics - therapeutic use ; Neuralgia - drug therapy ; Neurology ; Neurology/Neurosurgery ; Pain ; Patients ; Receptors, N-Methyl-D-Aspartate - metabolism ; Systematic review ; Time Factors ; Virology</subject><ispartof>PLoS medicine, 2005-07, Vol.2 (7), p.e164-e164</ispartof><rights>2005 Hempenstall et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Citation: Hempenstall K, Nurmikko TJ, Johnson RW, A'Hern RP, Rice AS (2005) Analgesic Therapy in Postherpetic Neuralgia: A Quantitative Systematic Review. PLoS Med 2(7): e164. doi:10.1371/journal.pmed.0020164</rights><rights>Copyright: © 2005 Hempenstall et al. 2005</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c615t-b60b04591182c642e987ca8480f2cedc73e28ffca9d1941e405e24c864b848863</citedby><cites>FETCH-LOGICAL-c615t-b60b04591182c642e987ca8480f2cedc73e28ffca9d1941e405e24c864b848863</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1181872/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1181872/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79342,79343</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16013891$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hempenstall, Kathleen</creatorcontrib><creatorcontrib>Nurmikko, Turo J</creatorcontrib><creatorcontrib>Johnson, Robert W</creatorcontrib><creatorcontrib>A'Hern, Roger P</creatorcontrib><creatorcontrib>Rice, Andrew S C</creatorcontrib><title>Analgesic therapy in postherpetic neuralgia: a quantitative systematic review</title><title>PLoS medicine</title><addtitle>PLoS Med</addtitle><description>Postherpetic neuralgia (PHN) is a complication of acute herpes zoster, which is emerging as a preferred clinical trial model for chronic neuropathic pain. Although there are published meta-analyses of analgesic therapy in PHN, and neuropathic pain in general, the evidence base has been substantially enhanced by the recent publication of several major trials. Therefore, we have conducted a systematic review and meta-analysis for both efficacy and adverse events of analgesic therapy for PHN. We systematically searched databases (MEDLINE 1966-2004, EMBASE 1988-2004, CINAHL 1982-2002, and PubMed [29 October 2004]) for trials of PHN. We also searched references of retrieved studies and review articles for further trials. We included trials that examined adult patients with PHN of greater duration than 3 mo, that were blinded, randomised, and had at least one measure of pain outcome. Dichotomous pain outcome data were extracted for 50% decrease in baseline pain using a hierarchy of pain/pain-relief measurement tools. Where available, dichotomous data were also collected for adverse events. Calculated estimates of efficacy included relative benefit and number needed to treat. Of 62 studies identified, 35 were randomised controlled trials. Of these, 31 were placebo controlled and suitable for meta-analysis, from which it was possible to extract dichotomous efficacy outcome data from 25. This meta-analysis revealed that there is evidence to support the use of the following orally administered therapies: tricyclic antidepressants, "strong" opioids, gabapentin, tramadol, and pregabalin. Topical therapies associated with efficacy were lidocaine 5% patch and capsaicin. Finally, a single study of spinal intrathecal administration of lidocaine and methyl prednisolone demonstrated efficacy, although this has yet to be replicated. Data suggest that the following therapies are not associated with efficacy in PHN: certain NMDA receptor antagonists (e.g., oral memantine, oral dextromethorphan, intravenous ketamine), codeine, ibuprofen, lorazepam, certain 5HT1 receptor agonists, and acyclovir. Topical administration of benzydamine, diclofenac/diethyl ether, and vincristine (iontophoresis) are similarly not associated with efficacy, nor are intrathecal administration of lidocaine alone or epidural administration of lidocaine and methylprednisolone, intravenous therapy with lidocaine, subcutaneous injection of Cronassial, or acupuncture. However, many of the trials that demonstrated a lack of efficacy represented comparatively low numbers of patient episodes or were single-dose studies, so it may be appropriate to regard such interventions as "not yet adequately tested" rather than demonstrating "no evidence of efficacy." Topical aspirin/diethyl ether has not been adequately tested. The evidence base supports the oral use of tricyclic antidepressants, certain opioids, and gabapentinoids in PHN. Topical therapy with lidocaine patches and capsaicin is similarly supported. Intrathecal administration of methylprednisolone appears to be associated with high efficacy, but its safety requires further evaluation.</description><subject>Analgesics</subject><subject>Analgesics - pharmacology</subject><subject>Antidepressants</subject><subject>Antidepressive Agents - therapeutic use</subject><subject>Antidepressive Agents, Tricyclic - therapeutic use</subject><subject>Clinical Trials as Topic</subject><subject>Herpes viruses</subject><subject>Herpes Zoster - drug therapy</subject><subject>Humans</subject><subject>Lidocaine - therapeutic use</subject><subject>Meta-analysis</subject><subject>Methylprednisolone - administration &amp; dosage</subject><subject>Narcotics</subject><subject>Narcotics - therapeutic use</subject><subject>Neuralgia - drug therapy</subject><subject>Neurology</subject><subject>Neurology/Neurosurgery</subject><subject>Pain</subject><subject>Patients</subject><subject>Receptors, N-Methyl-D-Aspartate - metabolism</subject><subject>Systematic review</subject><subject>Time Factors</subject><subject>Virology</subject><issn>1549-1676</issn><issn>1549-1277</issn><issn>1549-1676</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNptkk9v1DAQxS0EoqXwDRBEqtTbLv4Xx-aAVFUFKrXiAmdr4ky2XmXj1E4W7bevtxugRT3ZHv_m2fP0CHnP6JKJin1ahyn20C2HDTZLSjllSr4gx6yUZsFUpV4-2h-RNymtM2Sooa_JEVOUCW3YMbk5zxorTN4V4y1GGHaF74shpP1pwDHXe5xiZjx8LqC4m6Af_Qij32KRdmnEDeyhiFuPv9-SVy10Cd_N6wn59fXy58X3xfWPb1cX59cLp1g5LmpFaypLw5jmTkmORlcOtNS05Q4bVwnkum0dmIYZyVDSErl0Wsk6Q1qJE_LxoDt0IdnZiWQZ15pWohQyE1cHogmwtkP0G4g7G8Dbh0KIKwsxf7xDazQYToU0oixlyQGyu7SudF0L0KVsstaX-bWpzmY77MdsyBPRpze9v7WrsLV5PqYrngXOZoEY7iZMo9345LDroMcwJas05Yo9gKf_gc_PJg-UiyGliO3frzBq99n402X32bBzNnLbh8dj_GuawyDuAajlt1Y</recordid><startdate>20050701</startdate><enddate>20050701</enddate><creator>Hempenstall, Kathleen</creator><creator>Nurmikko, Turo J</creator><creator>Johnson, Robert W</creator><creator>A'Hern, Roger P</creator><creator>Rice, Andrew S C</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><scope>CZK</scope></search><sort><creationdate>20050701</creationdate><title>Analgesic therapy in postherpetic neuralgia: a quantitative systematic review</title><author>Hempenstall, Kathleen ; Nurmikko, Turo J ; Johnson, Robert W ; A'Hern, Roger P ; Rice, Andrew S C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c615t-b60b04591182c642e987ca8480f2cedc73e28ffca9d1941e405e24c864b848863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Analgesics</topic><topic>Analgesics - pharmacology</topic><topic>Antidepressants</topic><topic>Antidepressive Agents - therapeutic use</topic><topic>Antidepressive Agents, Tricyclic - therapeutic use</topic><topic>Clinical Trials as Topic</topic><topic>Herpes viruses</topic><topic>Herpes Zoster - drug therapy</topic><topic>Humans</topic><topic>Lidocaine - therapeutic use</topic><topic>Meta-analysis</topic><topic>Methylprednisolone - administration &amp; dosage</topic><topic>Narcotics</topic><topic>Narcotics - therapeutic use</topic><topic>Neuralgia - drug therapy</topic><topic>Neurology</topic><topic>Neurology/Neurosurgery</topic><topic>Pain</topic><topic>Patients</topic><topic>Receptors, N-Methyl-D-Aspartate - metabolism</topic><topic>Systematic review</topic><topic>Time Factors</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hempenstall, Kathleen</creatorcontrib><creatorcontrib>Nurmikko, Turo J</creatorcontrib><creatorcontrib>Johnson, Robert W</creatorcontrib><creatorcontrib>A'Hern, Roger P</creatorcontrib><creatorcontrib>Rice, Andrew S C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><collection>PLoS Medicine</collection><jtitle>PLoS medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hempenstall, Kathleen</au><au>Nurmikko, Turo J</au><au>Johnson, Robert W</au><au>A'Hern, Roger P</au><au>Rice, Andrew S C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Analgesic therapy in postherpetic neuralgia: a quantitative systematic review</atitle><jtitle>PLoS medicine</jtitle><addtitle>PLoS Med</addtitle><date>2005-07-01</date><risdate>2005</risdate><volume>2</volume><issue>7</issue><spage>e164</spage><epage>e164</epage><pages>e164-e164</pages><issn>1549-1676</issn><issn>1549-1277</issn><eissn>1549-1676</eissn><abstract>Postherpetic neuralgia (PHN) is a complication of acute herpes zoster, which is emerging as a preferred clinical trial model for chronic neuropathic pain. Although there are published meta-analyses of analgesic therapy in PHN, and neuropathic pain in general, the evidence base has been substantially enhanced by the recent publication of several major trials. Therefore, we have conducted a systematic review and meta-analysis for both efficacy and adverse events of analgesic therapy for PHN. We systematically searched databases (MEDLINE 1966-2004, EMBASE 1988-2004, CINAHL 1982-2002, and PubMed [29 October 2004]) for trials of PHN. We also searched references of retrieved studies and review articles for further trials. We included trials that examined adult patients with PHN of greater duration than 3 mo, that were blinded, randomised, and had at least one measure of pain outcome. Dichotomous pain outcome data were extracted for 50% decrease in baseline pain using a hierarchy of pain/pain-relief measurement tools. Where available, dichotomous data were also collected for adverse events. Calculated estimates of efficacy included relative benefit and number needed to treat. Of 62 studies identified, 35 were randomised controlled trials. Of these, 31 were placebo controlled and suitable for meta-analysis, from which it was possible to extract dichotomous efficacy outcome data from 25. This meta-analysis revealed that there is evidence to support the use of the following orally administered therapies: tricyclic antidepressants, "strong" opioids, gabapentin, tramadol, and pregabalin. Topical therapies associated with efficacy were lidocaine 5% patch and capsaicin. Finally, a single study of spinal intrathecal administration of lidocaine and methyl prednisolone demonstrated efficacy, although this has yet to be replicated. Data suggest that the following therapies are not associated with efficacy in PHN: certain NMDA receptor antagonists (e.g., oral memantine, oral dextromethorphan, intravenous ketamine), codeine, ibuprofen, lorazepam, certain 5HT1 receptor agonists, and acyclovir. Topical administration of benzydamine, diclofenac/diethyl ether, and vincristine (iontophoresis) are similarly not associated with efficacy, nor are intrathecal administration of lidocaine alone or epidural administration of lidocaine and methylprednisolone, intravenous therapy with lidocaine, subcutaneous injection of Cronassial, or acupuncture. However, many of the trials that demonstrated a lack of efficacy represented comparatively low numbers of patient episodes or were single-dose studies, so it may be appropriate to regard such interventions as "not yet adequately tested" rather than demonstrating "no evidence of efficacy." Topical aspirin/diethyl ether has not been adequately tested. The evidence base supports the oral use of tricyclic antidepressants, certain opioids, and gabapentinoids in PHN. Topical therapy with lidocaine patches and capsaicin is similarly supported. Intrathecal administration of methylprednisolone appears to be associated with high efficacy, but its safety requires further evaluation.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>16013891</pmid><doi>10.1371/journal.pmed.0020164</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1549-1676
ispartof PLoS medicine, 2005-07, Vol.2 (7), p.e164-e164
issn 1549-1676
1549-1277
1549-1676
language eng
recordid cdi_plos_journals_1288073534
source MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Public Library of Science (PLoS)
subjects Analgesics
Analgesics - pharmacology
Antidepressants
Antidepressive Agents - therapeutic use
Antidepressive Agents, Tricyclic - therapeutic use
Clinical Trials as Topic
Herpes viruses
Herpes Zoster - drug therapy
Humans
Lidocaine - therapeutic use
Meta-analysis
Methylprednisolone - administration & dosage
Narcotics
Narcotics - therapeutic use
Neuralgia - drug therapy
Neurology
Neurology/Neurosurgery
Pain
Patients
Receptors, N-Methyl-D-Aspartate - metabolism
Systematic review
Time Factors
Virology
title Analgesic therapy in postherpetic neuralgia: a quantitative systematic review
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T00%3A18%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Analgesic%20therapy%20in%20postherpetic%20neuralgia:%20a%20quantitative%20systematic%20review&rft.jtitle=PLoS%20medicine&rft.au=Hempenstall,%20Kathleen&rft.date=2005-07-01&rft.volume=2&rft.issue=7&rft.spage=e164&rft.epage=e164&rft.pages=e164-e164&rft.issn=1549-1676&rft.eissn=1549-1676&rft_id=info:doi/10.1371/journal.pmed.0020164&rft_dat=%3Cproquest_plos_%3E68026172%3C/proquest_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1288073534&rft_id=info:pmid/16013891&rft_doaj_id=oai_doaj_org_article_98a920349355452aa3710b78bb3a854d&rfr_iscdi=true